The Supreme Court on Tuesday appreciated the "marked improvement" in the unconditional public apology published in newspapers by yoga guru Ramdev, his aide Balkrishna and Patanjali Ayurved Ltd in the misleading advertisements case.
A bench of justices Hima Kohli and Ahsanuddin Amanullah told senior advocate Mukul Rohatgi, appearing for Ramdev, Balkrishna and Patanjali Ayurved Ltd, that language of the apology was adequate and the names were also there in it.
"I don't know the second apology is on whose vetting. There has been marked improvement," Justice Amanullah said, adding, "We appreciate that. Now finally they have understood."
He said earlier when the apology was published, only the company's name was there.
"Now the names have come. It is a marked improvement, we appreciate that," Justice Amanullah observed, adding, "The language is adequate."
During the hearing, the apex court asked the firm's counsel as to why they have e-filed the apology published in newspapers when the court had on April 23 specifically asked that the original has to be filed.
"This is not compliance of our order," Justice Kohli observed.
"There is too much of communication gap Mr Rohatgi... Speaking for myself, I raise my hands now. Too much of an indulgence," Justice Amanullah said.
The bench noted in its order that the firm's lawyer have conceded that there has been some misunderstanding of the orders passed by the court by his briefing counsel and one more opportunity be given to comply with the order by filing the original page of each newspaper in which the public apology has been published.
"The registry is directed to accept the said document when filed," the bench said and posted the matter for hearing on May 7.
Rohatgi sought exemption from personal appearance for Ramdev and Balkrishna for the next date of hearing in the matter.
"The exemption is granted limited to the next date of hearing," the bench said.
The apex court is hearing a plea filed in 2022 by the Indian Medical Association alleging a smear campaign against the Covid vaccination drive and modern systems of medicine.
While hearing the matter on April 23, the top court had said the public apology published in newspapers were not on record and asked those to be filed within two days.
Patanjali Ayurved Ltd had assured the top court on November 21 last year that it will not violate any law, especially those relating to advertising or branding of products manufactured and marketed by it.
It had also assured the bench that "no casual statements claiming medicinal efficacy or against any system of medicine will be released to the media in any form".
The top court had said Patanjali Ayurved Ltd is "bound down to such assurance".
The non-observance of the specific undertaking and subsequent media statements had irked the bench, which later issued notices to show cause why contempt proceedings should be not initiated against them.
On March 19, the top court had directed Ramdev and Balkrishna, who is the managing director of Patanjali Ayurved Ltd, to appear before it after taking exception to the company's failure to respond to the notice issued in the case relating to advertisements of the firm's products and their medicinal efficacy.
The top court had said it deemed it appropriate to issue Ramdev a show cause notice as advertisements issued by Patanjali, which were in the teeth of the undertaking given to the court on November 21, 2023, reflect an endorsement by him.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)